Anthem Biosciences kicked off its stock market journey on a high note, with shares rising 3.3% intraday on Monday to touch ₹746.70 on the BSE. This follows a robust listing at ₹723 a sharp 27% premium over its IPO price of ₹570 signaling strong investor confidence.
Early investors in the IPO are now sitting on gains of roughly 31%, according to data from The Economic Times. The IPO itself drew remarkable interest, getting subscribed over 67 times across all investor categories a clear sign of the company’s appeal.
The offering also was an offer-for-sale (OFS) and the proceeds received were paid to the stockholders who were already in place. Before the listing, there were anchor investors who infused 1016 crore of rupees hence, increasing the credibility and demand.
Should You Invest in Anthem Biosciences Now?
According to Prashanth Tapse, Senior VP (Research) at Mehta Equities, the post-listing valuation might seem steep, but it’s supported by Anthem’s solid fundamentals, unique capabilities, and its positioning in a high-growth industry.
He recommends holding the stock from a long-term perspective. “For patient investors, Anthem represents a structurally sound opportunity within the rapidly growing Indian CRDMO (Contract Research, Development & Manufacturing Organization) sector,” Tapse noted.
Market analysts have suggested a near-term price target of ₹900, while long-term investors could see the stock cross ₹1,000 provided the company maintains its growth trajectory.
However, for those who missed out on the IPO, experts suggest waiting for price consolidation before entering the stock.
Business Snapshot
Anthem Biosciences was founded in 2006 to run across the pharma value chain, including drug discovery to commercial-scale production, biologics as well as small- molecule drugs.
In the fiscal year that ended on March 31, 2025 (FY25) the company had notable financial performance: revenue has grown 30 % year over year to 1,930 crore, net profit has grown 23 % to 451 crore, EBITDA was 684 crore with a strong margin of 37 % and its debt levels were manageable, indicating the strength of its financials.
